false
0001445815
0001445815
2026-11-16
2026-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 16, 2026
BIOXYTRAN,
INC.
(Exact
Name of Registrant as Specified in Charter)
| Nevada |
|
001-35027 |
|
26-2797630 |
| (State
or Other Jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
Incorporation) |
|
File
Number) |
|
Identification
Number) |
| 75
Second Ave, Suite 605, Needham, MA |
|
02494 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code 617-454-1199
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| |
|
|
|
|
| Common
Stock, par value $0.001 |
|
BIXT |
|
OTCQB |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events
On
November 16, 2026, the Company issued a press-release over Globe Newswire, enclosed hereto as Exhibit 99.1, under the title:
Bioxytran
Turns Science into Everyday Wellness with Launch of Its First Two Nutraceutical Products
Item
9.01 Financial Statements and Exhibits.
Exhibit
Number |
|
Description |
| |
|
|
| 99.1 |
* |
Press Release dated November 16, 2026, entitled “Bioxytran Turns Science into Everyday Wellness with Launch of Its First Two Nutraceutical Products”. |
| |
|
|
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
| * |
Filed
as an exhibit hereto. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
BIOXYTRAN,
INC. |
| |
|
|
| |
By: |
/s/
David Platt, Ph.D. |
| |
|
David
Platt, Ph.D., its Chief Executive Officer |
| |
|
|
| Date
November 16, 2026 |
|
|
EXHIBIT
99.1
Bioxytran
Turns Science into Everyday Wellness with Launch of Its First Two Nutraceutical Products
Company
applies its carbohydrate-chemistry expertise to consumer wellness with a post-meal blood sugar supplement and an immune support supplement
Boston,
Mass., November 16, 2026 – Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage
biotechnology company developing platform technologies spanning Glycovirology, hypoxia, and degenerative diseases, today announced the
launch two nutraceutical products: A-SUQAR, a supplement formulated to help maintain healthy blood sugar levels after meals, and
V-LO, a supplement formulated to support healthy immune function. These statements have not been evaluated by the Food and Drug
Administration, and the products are not intended to diagnose, treat, cure, or prevent any disease.
The
launch marks Bioxytran’s expansion beyond its pharmaceutical pipeline into the consumer wellness market. A-SUQAR and V-LO are available
beginning immediately at https://bioxytran.myshopify.com/
“For
years, our team has worked on complex therapeutics for critical care and infectious diseases. Today we are bringing that same science
directly to people’s doorsteps,” said David Platt, Ph.D., Chief Executive Officer of Bioxytran. “Our entry into nutraceuticals
is driven by a simple principle: apply rigorous scientific standards to everyday health. We have held these products to the same diligence
we apply to our drug programs, so consumers get a high-quality, science-backed supplement they can trust.”
The
Products
A-SUQAR
– Metabolic Support. A-SUQAR is designed to help maintain healthy blood sugar levels after meals. It works by slowing the breakdown
and absorption of dietary sugars in the intestine, supporting healthy metabolism and balanced energy throughout the day.
V-LO
– Immune Support. V-LO is formulated to support the body’s natural immune defenses, helping people stay strong and resilient
through the seasons.
Built
on Safety and Quality
Both
products draw on Bioxytran’s expertise in complex carbohydrate chemistry and are formulated with ingredients that are Generally
Recognized as Safe (GRAS). The products are manufactured in a certified facility and were tested by third independent party.
Message
to Shareholders and Friends
“Our
shareholders and friends, are the backbone of Bioxytran,” said Dr. Platt. “We believe the best way to show the value of our
work is to experience it firsthand. I invite you to try these products and make them part of your everyday routine. Thank you for your
continued faith in Bioxytran. We look forward to sharing more updates on our progress.”
About
Bioxytran, Inc.
Bioxytran,
Inc. (OTCQB: BIXT) is a clinical-stage biotechnology company developing platform technologies spanning Glycovirology, hypoxia, and degenerative
diseases. The Company is now also applying its scientific expertise to high-quality nutraceutical products. For more information, visit
www.bioxytraninc.com.
Forward-Looking
Statements
This
press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding the launch, availability, market acceptance, and potential benefits of the Company’s nutraceutical
products and the Company’s growth. Words such as “believe,” “expect,” “intend,” “plan,”
“may,” “will,” and similar expressions identify forward-looking statements. These statements are based on current
expectations and involve risks and uncertainties, including risks related to manufacturing and supply, consumer demand, competition,
regulatory requirements applicable to dietary supplements, and the Company’s ability to fund its operations. Actual results may
differ materially. Additional risks are described in the Company’s filings with the U.S. Securities and Exchange Commission, including
its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Bioxytran undertakes no obligation to update any forward-looking
statement, except as required by law.
Contact
David
Platt, PhD/CEO
Bioxytran,
Inc.
Info@bioxytraninc.com
Phone:
617.454.1199
www.bioxytraninc.com